Companies / Switzerland
First Biosimilar Approved In Europe
April 2006 | Product LaunchThe EC has registered Swiss firm Sandoz' Omnitrope (somatropin) for the treatment of growth hormone deficiency, marking the first approval of a biosimilar in Europe. Launch in Austria and Germany is expected
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
